Tvardi Therapeutics (NASDAQ:TVRD) Shares Cross Above 50 Day Moving Average – What’s Next?

Tvardi Therapeutics, Inc. (NASDAQ:TVRD)’s stock price crossed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $1.28 and traded as high as $1.61. Tvardi Therapeutics shares last traded at $1.41, with a volume of 1,863,006 shares changing hands.

Analysts Set New Price Targets

TVRD has been the topic of a number of research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, October 2nd. Lucid Cap Mkts upgraded shares of Tvardi Therapeutics to a “strong-buy” rating in a report on Tuesday, September 8th. Wall Street Zen lowered shares of Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, November 1st. Chardan Capital started coverage on Tvardi Therapeutics in a report on Tuesday, October 20th. They issued a “buy” rating on the stock. Finally, BTIG Research dropped their price target on Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $9.40.

Tvardi Therapeutics Stock Performance

The stock has a 50 day moving average of $1.28 and a two-hundred day moving average of $2.66. The stock has a market cap of $18.81 million, a PE ratio of -0.51 and a beta of 0.37.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04). Analysts expect that Tvardi Therapeutics, Inc. will post -2.23 EPS for the current fiscal year.

Institutional Trading of Tvardi Therapeutics

Hedge funds have recently modified their holdings of the business. Susquehanna International Group LLP acquired a new position in Tvardi Therapeutics in the 2nd quarter worth about $63,000. BlackRock Inc. acquired a new stake in shares of Tvardi Therapeutics during the 2nd quarter valued at about $181,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at approximately $34,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases involving abnormal STAT3 signaling. STAT3 is a protein that can contribute to tumor growth, treatment resistance and immune suppression, making it a potential target for drug development.

The company’s lead investigational product is TTI-101, an orally administered small-molecule inhibitor designed to block STAT3 activity. Tvardi is evaluating TTI-101 in clinical studies for solid tumors, including hepatocellular carcinoma and other advanced cancers.